The University of Texas MD Anderson Cancer Center has announced a strategic collaboration with Federation Bio for the development of a new microbiome treatment for immunotherapy-resistant cancer patients.
The collaboration is aimed at designing and developing a complex, synthetic microbial consortium to expand the number of cancer patients who respond to immunotherapy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt combines the expertise and capabilities of Platform for Innovative Microbiome and Translational Research (PRIME-TR) of MD Anderson with the ACT (anaerobic co-culture technology) platform of Federation Bio.
Under the agreement, both Federation Bio and MD Anderson will rationally design a complex bacteria consortium derived from a donor faecal sample, which showed the ability to improve immunotherapy responses in patients with cancer through FMT in a study.
Federation Bio will leverage its ACT platform for manufacturing the consortium from purified cell lines, creating a therapy that includes the complete metabolic complexity of the identified microbiome.
The platform enables highly controlled bacterial consortia production, which is designed for addressing a wide range of disorders and diseases.
Federation Bio CEO Emily Drabant Conley said: “We are proud to be collaborating with MD Anderson, an institution that is leading the charge globally to advance microbiome-based approaches that could dramatically improve outcomes for cancer patients.
“We’ve demonstrated that our ACT platform enables the manufacture of complex, rationally designed microbial consortia at scale through the manufacture of FB-001, and this collaboration enables us to explore its potential in oncology, where there is both a high unmet need and evidence supporting the critical role of the microbiome in driving therapeutic response.”
The company previously used the ACT platform for designing and manufacturing the investigational oral therapy, FB-001, which comprises 148 bacterial strains isolated from multiple healthy donors.
